Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016

Krakow, 1 February 2016 – Selvita S.A. (WSE: SLV), the largest drug discovery company in Central and Eastern Europe, today announced that Pawel Przewiezlikowski, Chief Executive Officer of the company, will present at the upcoming 18th Annual BIO CEO & Investor Conference, which will take place on February 8 – 9, at the Waldorf Astoria New York.

Mr Przewiezlikowski will present on Tuesday, February 9, at 09:30 a.m. in the Duke of Windsor room, providing a corporate overview of the Company’s recent activities, strategic plans concerned with the further development of its R&D programs, including these targeting PIM/FLT3, CDK8 and MNK1/2 kinases in oncology, extended or new strategic discovery collaborations with Merck and H3 Biomedicine, as well as further growth of Selvita’s research service business.

A live audio webcast of the Selvita presentation will be accessible at:

The audio webcast will be archived shortly after the live event and will be available for 90 days through the Selvita website:

About BIO CEO & Investor Conference

The BIO CEO & Investor Conference is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Its mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. BIO One-on-One PartneringTM provides an opportunity to arrange meetings between investors; companies; and industry BD, licensing and therapeutic franchise heads.

About Selvita

Selvita is a drug discovery company engaged in the research and development of breakthrough therapies in the area of oncology, as well as provision of integrated drug discovery services. Selvita was established and 2007 and currently employs 311 people, including 91 PhDs, with extensive experience in the area of life sciences. Selvita has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2016. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita offices are located in Greater Boston Area, San Francisco Area, Cambridge, UK, and Krakow, Poland. The company is listed on the Warsaw Stock Exchange (WSE:SLV).